| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALNY | Common Stock | Award | $0 | +5.42K | +49.14% | $0.00 | 16.4K | Dec 21, 2021 | Direct | F1 |
| transaction | ALNY | Common Stock | Tax liability | -$457K | -2.42K | -14.69% | $189.13 | 14K | Dec 22, 2021 | Direct | F2 |
| transaction | ALNY | Common Stock | Tax liability | -$191 | -1 | -0.01% | $190.96 | 14K | Dec 22, 2021 | Direct | F2 |
| transaction | ALNY | Common Stock | Tax liability | -$22.8K | -122 | -0.87% | $186.55 | 13.9K | Dec 22, 2021 | Direct | F2 |
| holding | ALNY | Common Stock | 407 | Dec 21, 2021 | by Managed Account | F3 |
| Id | Content |
|---|---|
| F1 | On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021. |
| F2 | Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. |
| F3 | Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |